Ambrx Biopharma Inc.
NYSE:AMAM
28 (USD) • At close March 6, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|
| Assets: | ||||
| Current Assets: | ||||
| Cash & Cash Equivalents
| 55.61 | 170.064 | 90.462 | 15.493 |
| Short Term Investments
| 28.873 | 0 | 0 | 0 |
| Cash and Short Term Investments
| 84.483 | 170.064 | 90.462 | 15.493 |
| Net Receivables
| 2.05 | 1.343 | 0.982 | 1.391 |
| Inventory
| 3.731 | 5.169 | 1.442 | 1.127 |
| Other Current Assets
| 0.319 | 0.23 | 0.191 | 0.146 |
| Total Current Assets
| 90.583 | 176.806 | 93.077 | 18.157 |
| Non-Current Assets: | ||||
| Property, Plant & Equipment, Net
| 14.012 | 15.721 | 3.491 | 4.971 |
| Goodwill
| 0 | 0 | 0 | 0 |
| Intangible Assets
| 25.25 | 35.962 | 36.829 | 38.28 |
| Goodwill and Intangible Assets
| 25.25 | 35.962 | 36.829 | 38.28 |
| Long Term Investments
| 16.793 | 0 | 0 | 0 |
| Tax Assets
| 0 | 0 | 0 | 0 |
| Other Non-Current Assets
| 0.339 | 0.53 | 0.624 | 0.319 |
| Total Non-Current Assets
| 56.394 | 52.213 | 40.944 | 43.57 |
| Total Assets
| 146.977 | 229.019 | 134.021 | 61.727 |
| Liabilities & Equity: | ||||
| Current Liabilities: | ||||
| Account Payables
| 3.205 | 5.272 | 2.82 | 5.39 |
| Short Term Debt
| 1.734 | 0.915 | 1.595 | 1.453 |
| Tax Payables
| 1.703 | 0.556 | 0.168 | 0.146 |
| Deferred Revenue
| 0.407 | 4.267 | 6.47 | 4.214 |
| Other Current Liabilities
| 11.314 | 14.125 | 2.375 | 3.885 |
| Total Current Liabilities
| 16.66 | 24.579 | 13.26 | 14.942 |
| Non-Current Liabilities: | ||||
| Long Term Debt
| 10.245 | 12.212 | 1.598 | 3.193 |
| Deferred Revenue Non-Current
| 1.342 | 1.381 | 3.261 | 6.797 |
| Deferred Tax Liabilities Non-Current
| 0.88 | 0.88 | 0.88 | 0.808 |
| Other Non-Current Liabilities
| 0 | 0 | 253.169 | 0 |
| Total Non-Current Liabilities
| 12.467 | 14.473 | 258.908 | 10.798 |
| Total Liabilities
| 29.127 | 39.052 | 272.168 | 25.74 |
| Equity: | ||||
| Preferred Stock
| 0 | 0 | 253.031 | 0 |
| Common Stock
| 0.027 | 0.027 | 0 | 0.014 |
| Retained Earnings
| -291.628 | -213.632 | -145.553 | -129.01 |
| Accumulated Other Comprehensive Income/Loss
| -1.302 | -0.79 | -0.686 | -0.843 |
| Other Total Stockholders Equity
| 410.753 | 404.362 | -246.226 | 163.263 |
| Total Shareholders Equity
| 117.85 | 189.967 | -139.434 | 33.424 |
| Total Equity
| 117.85 | 189.967 | -138.147 | 35.987 |
| Total Liabilities & Shareholders Equity
| 146.977 | 229.019 | 134.021 | 61.727 |